ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial An International, Phase 3, Multicenter, Randomized, Open-Label Trial Comparing Balixafortide in combination with Eribulin versus Eribulin alone in Patients with HER2 negative, Locally Recurrent or Metastatic Breast Cancer
EudraCT number 2018-004211-42
Protocol number POL6326-009
Sponsor Polyphor Ltd., Hegenheimermattweg 125, Allschwil, CH-4123, Switzerland
Indications Oncology
Diagnosis metastatic breast cancer
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Year of receiving the request to Institute (SÚKL) 2019
Date of approval by Institute (SÚKL) 6.3.2020
Date of approval by EC
Date of initiation CT in ČR 17.6.2020
Date of ending CT in ČR
Sites Fakultní nemocnice Hradec Králové,Klinika onkologie a radioterapie,Sokolská 581, Hradec Králové,500 05
Fakultní nemocnice v Motole ,Onkologická klinika,V Úvalu 84,Praha 5,150 06
Multiscan s.r.o.,Ambulance klinické onkologie, K Nemocnici 1106/14,Hořovice,268 31
Thomayerova nemocnice,Onkologická klinika 1. LF UK a TN,Vídeňská 800,Praha 4,140 59

‹‹ Back to list